OverviewChartProfileKey statisticsFinancialsTechnicalNewsTraderScreen

Opko Health Inc/  US68375N1037  /

NASDAQ
23/05/2024  22:00:00 Chg. -0.0400 Volume Bid11:46:14 Ask11:46:14 High Low
1.2800USD -3.03% 2.79 mill.
Turnover: 3.35 mill.		 1.2500Bid Size: 1,000 1.3200Ask Size: 1,500 1.3300 1.2600
GlobeNewswire 15/05 Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
GlobeNewswire 13/05 Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Tr...
GlobeNewswire 10/05 Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates
GlobeNewswire 07/05 OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results
GlobeNewswire 03/05 OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024
GlobeNewswire 08/04 Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the...
GlobeNewswire 26/03 Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FD...
GlobeNewswire 20/03 Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatm...
GlobeNewswire 08/03 Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
GlobeNewswire 05/03 AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the ...
GlobeNewswire 04/03 Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire 28/02 AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors
GlobeNewswire 27/02 OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results
GlobeNewswire 22/02 OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024
GlobeNewswire 02/02 SAB Biotherapeutics Announces Executive Leadership Change
GlobeNewswire 30/01 Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
GlobeNewswire 09/01 OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 ...
GlobeNewswire 08/01 OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire 05/01 OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029
GlobeNewswire 03/01 OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029
GlobeNewswire 03/01 Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
GlobeNewswire 26/12/2023 Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025
GlobeNewswire 29/11/2023 Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatme...
GlobeNewswire 14/11/2023 Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision a...
GlobeNewswire 09/11/2023 Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-...